Technical Analysis for EMMA - Emmaus Life Sciences Inc

Grade Last Price % Change Price Change
C 1.45 -3.97% -0.0600
EMMA closed down 3.97 percent on Thursday, December 2, 2021, on 84 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical EMMA trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -3.97%
Upper Bollinger Band Walk Strength -3.97%
Inside Day Range Contraction -3.97%
Wide Bands Range Expansion -3.97%
Older End-of-Day Signals for EMMA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Emmaus Life Sciences Inc Description

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Health Medical Specialties Pharmaceutical Medication Restore Therapeutic Product Therapeutic Products Orphan Diseases Orphan Disease Therapeutic Cell Sheet Technology Corneal Diseases Diverticulosis Endari Glutamine Rare And Orphan Diseases Sickle Cell Disease Treatment Of Corneal Diseases

Is EMMA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.0
52 Week Low 1.0
Average Volume 26,032
200-Day Moving Average 1.4925
50-Day Moving Average 1.4683
20-Day Moving Average 1.3731
10-Day Moving Average 1.4880
Average True Range 0.3846
ADX 33.26
+DI 46.4583
-DI 6.4093
Chandelier Exit (Long, 3 ATRs) 2.8462
Chandelier Exit (Short, 3 ATRs) 2.2838
Upper Bollinger Bands 1.7908
Lower Bollinger Band 0.9554
Percent B (%b) 0.59
BandWidth 60.8404
MACD Line 0.0449
MACD Signal Line 0.0029
MACD Histogram 0.042
Fundamentals Value
Market Cap 70.28 Million
Num Shares 48.5 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -1.38
Price-to-Sales 0.92
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.0200
Resistance 3 (R3) 2.0333 1.8567 1.9250
Resistance 2 (R2) 1.8567 1.7115 1.8500 1.8933
Resistance 1 (R1) 1.6533 1.6218 1.5650 1.6400 1.8617
Pivot Point 1.4767 1.4767 1.4325 1.4700 1.4767
Support 1 (S1) 1.2733 1.3315 1.1850 1.2600 1.0383
Support 2 (S2) 1.0967 1.2418 1.0900 1.0067
Support 3 (S3) 0.8933 1.0967 0.9750
Support 4 (S4) 0.8800